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ABSTRACT 
 
Establishment of Individual Prediction Model for Treatment Response 
in HBeAg-Positive Chronic Hepatitis B Patients on 
Lamivudine Monotherapy 
 
Wonseok Kang 
 
Department of Medicine 
The Graduate School, Yonsei University  
 
(Directed by Professor Kwang-Hyub Han) 
 
Background: Although the emergence of lamivudine-resistant strains is 
becoming a problem in the treatment of chronic hepatitis B, lamivudine is still 
the first-line drug in many countries, because of its long-term safety profile 
and relatively inexpensive cost. Therefore, it would be beneficial to screen 
lamivudine responders prior to lamivudine treatment. The aim of this study 
was to assess the predictors of lamivudine treatment response and to establish 
an individual prediction model for HBeAg seroconversion in HBeAg-positive 
chronic hepatitis B patients on lamivudine monotherapy. 
Methods: In this multi-center trial, retrospective analysis of 748 consecutive 
patients (Male:Female, 570:178) with HBeAg-positive chronic hepatitis B on 
lamivudine monotherapy was performed between January 1999 and August 
2004. The median age was 43.0 years (range, 19-79). Multivariate analysis 
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was conducted to identify factors associated with HBeAg seroconversion, and 
probability of HBeAg seroconversion was calculated in a logistic regression 
model. The probability (Pr) of HBeAg seroconversion was classified into high 
(Pr≥50%), intermediate (30<Pr<50%), and low (Pr≤30%) response group, and 
was then validated using a new set of patients, enrolled between January 2005 
and December 2006. 
Results: The duration of lamivudine monotherapy was 34.2 ± 0.7 months 
(mean ± SD). The cumulative HBeAg seroconversion rates were increased 
from 26.1% at 12 months to 50.7% at 96 months. In the multivariate analysis, 
age (OR=0.974, 95% CI: 0.961-0.988, p<0.001), pretreatment serum ALT 
level (OR=1.001, 95% CI: 1.000-1.002, p=0.014), and pretreatment serum 
HBV DNA level (OR=0.749, 95% CI: 0.651-0.862, p<0.001) were significant 
factors associated with HBeAg seroconversion. Based on the data from 748 
HBeAg-positive chronic hepatitis B patients, an individual prediction model 
was established. The cumulative HBeAg seroconversion rate at 72 months for 
high, intermediate, and low response group was 66.0%, 48.5%, and 21.8%, 
respectively (p<0.001). 
Conclusion: An individual prediction model was developed based on the 
predictors of HBeAg seroconversion in HBeAg-positive chronic hepatitis B 
patients on lamivudine monotherapy. This model seems feasible and may 
facilitate screening lamivudine responders prior to the commencement of 
antiviral treatment. 
---------------------------------------------------------------------------------------------- 
Key words : prediction model, chronic hepatitis B, lamivudine, antiviral 
therapy 
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I. INTRODUCTION 
 
Chronic hepatitis B virus (HBV) infection is a major public health problem 
worldwide affecting more than 400 million people, of whom approximately 
75% are of Asian ethnicity.
1-3
 Individuals chronically infected by HBV are at 
risk of developing chronic liver disease, cirrhosis and hepatocellular 
carcinoma.
4
  
The goal of therapy for chronic hepatitis B is to eliminate or significantly 
suppress viral replication and prevent the progression of liver disease to 
cirrhosis, hepatocellular, and death.
5
 Loss of HBsAg, although highly 
desirable, is rarely attained with short-term antiviral therapy, and thus, is not a 
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realistic goal for antiviral treatment. Therefore, the primary aim of treatment 
is to reduce and maintain serum HBV DNA at the lowest possible levels, to 
promote histologic improvement, and to promote alanine aminotransferase 
(ALT) normalization. Persistence of positive hepatitis B e antigen (HBeAg) 
and high HBV DNA level are well-known risk factors for progression of liver 
disease and development of hepatocellular carcinoma, and hence, in patients 
who are HBeAg-positive before antiviral therapy, an additional goal of 
treatment is achieving loss of HBeAg with seroconversion to the antibody to 
HBeAg (anti-HBe). HBeAg seroconversion is preferable, because 
achievement of complete HBeAg seroconversion indicates a high likelihood 
that the benefit will persist once the patient is off therapy, enabling the 
clinician to discontinue treatment at some point after the seroconversion.
6-9
  
Antiviral therapy in patients with chronic hepatitis B is associated with 
improved outcome. Currently, six drugs are available for the management of 
chronic HBV infection in Korea: interferon-alfa, pegylated interferon, 
lamivudine, adefovir dipivoxil, entecavir, and clevudine. 
For many years, interferon-alfa, the first agent approved for treating chronic 
hepatitis B, was the only treatment specifically approved for patients with 
chronic hepatitis B. However, it has been reported to be effective only in a 
minority of patients, and furthermore, virologic relapse after 
interferon-alfa-induced viral suppression is common in endemic areas of HBV 
infection, especially Korea.
10, 11
 
Lamivudine, the first nucleoside analogue approved for the treatment of 
chronic hepatitis B, inhibits viral reverse-transcriptase activity as a 
competitive inhibitor of deoxycytidine triphosphate.
12
 Since it was officially 
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introduced in Korea in the late 1990s, lamivudine has been widely prescribed 
for initial treatment for chronic hepatitis B infection. By suppressing HBV 
replication, lamivudine brings about decreased level or disappearance of HBV 
DNA in the patient’s serum, HBeAg, normalization of serum ALT level, and 
histological improvement.
13-15
 
As discontinuation of therapy often leads to reactivation of HBV, long-term 
therapy is necessary for many patients with chronic hepatitis B infection. Yet, 
the emergence of drug-resistant mutations from substitutions at M204I/V 
within the tyrosine-methionine-aspartate-aspartate (YMDD) motif of the HBV 
polymerase gene, has been a major limitation in long-term lamivudine 
treatment.
14-21
 The selection of lamivudine-resistant YMDD variants can lead 
to marked viral rebound, increases in serum ALT levels, hepatitis flares, or 
even liver decompensation and death from hepatic failure.
21-25
 As a result, 
newer nucleos(t)ide analogues, which are associated with more potent viral 
suppression and a lower chance of the emergence of drug resistant HBV 
variants, have been introduced to the market.
26-32
 
Despite the introduction of the newer nucleos(t)ide analogues, however, 
lamivudine is still used as the first-line drug for the treatment of chronic 
hepatitis B in many places, because of its well-established long-term safety 
and efficacy profile, and additionally, relatively inexpensive cost.
33
 Many 
patients have been successfully treated long-term in the past with lamivudine 
with persistently undetectable serum HBV DNA for many years. For the 
reason that there is a certain proportion of patients who shows long-term 
favorable response to lamivudine treatment, tailored the antiviral therapy 
according to the patient features and clinical circumstances is necessary.
34
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Hence, so as to maximize individualized therapy for chronic hepatitis B 
patients, it is still an important issue to screen patients who are more likely to 
be responsive to lamivudine with a lower chance of developing 
lamivudine-resistant variants before initiating the antiviral treatment. 
The aim of this study was to assess the predictors of lamivudine treatment 
response and to develop and validate an individual prediction model for 
HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients on 
lamivudine monotherapy. 
 
- 7 - 
 
 
II. MATERIALS AND METHODS 
 
1. Study Population 
In this multi-centered, retrospective cohort study, data were collected from 
consecutive patient files and medical records held at seven medical 
institutions in Korea, including Yonsei, Yeungnam, Keimyung, Hanyang, 
Soonchunhyang, Kwandong University and National Health Institute 
Corporation Ilsan Hospital. 748 patients with HBeAg-positive chronic 
hepatitis B who were given lamivudine 100 mg daily from January 1999 to 
August 2004 were selected for the study set. For the validation set, 396 
patients with HBeAg-positive chronic hepatitis B who started lamivudine 
therapy between January 2005 and December 2006 were consecutively 
enrolled, and data were collected. Patients were considered eligible if they 
were 18 years of age or older, had positive HBsAg and HBeAg for more than 
6 months, had elevated serum HBV DNA level (at least 1.4 x 10
5
 copies/mL), 
and had elevated serum ALT level more than twice the upper limit of normal 
for more than two successive months. Patients were excluded if they had 
decompensated liver cirrhosis, hepatocellular carcinoma, liver transplantation, 
or received immunosuppressive agents. Moreover, patients with co-infections 
such as human immunodeficiency virus (HIV), hepatitis C virus (HCV) or 
hepatitis D virus (HDV), or other concomitant liver diseases such as 
autoimmune liver disease and hemochromatosis were excluded. 
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2. Definition 
HBeAg seroconversion was defined as loss of HBeAg and detection of 
anti-HBe in the patient’s serum, which was previously HBeAg-positive and 
anti-HBe-negative. Virologic response was defined as undetectable serum 
HBV DNA levels. Virologic breakthrough was defined as increase in serum 
HBV DNA level by greater than 1.0 log10 copies/mL above nadir after 
achieving a virologic response during continued therapy.  
 
3. Study Methods 
A. Data collection 
The clinical and laboratory data of the patients were recorded with 
retrospective chart review. Clinical evaluation included general characteristics 
of the patients such as gender, age, family history, and treatment duration. 
Laboratory variables included serum biochemistry data such as serum ALT 
levels, serologic markers of HBV infection, and serum HBV DNA levels. 
HBsAg, anti-HBs, HBeAg, and anti-HBe were determined by commercially 
available enzyme immunoassays (Dade Behring, Marburg, Germany). Serum 
HBV DNA level was determined by detection of HBV DNA by Hybrid 
Capture II HBV DNA assay (Digene Diagnostics Inc., Bestivelle, MD, USA), 
and the lower limit of detection for HBV DNA test was 1.4 x 10
5
 copies/mL. 
The upper limit of normal for serum ALT was 40 IU/L. 
 
B. Statistical Analysis 
The values were expressed as mean ± standard error of mean or median 
(range) as appropriate. HBV DNA levels were reported as log10 copies/mL. 
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Continuous variables were compared with Student’s t-test and categorical 
variables with chi-squared test or Fisher’s exact test as appropriate. 
Time-to-event (survival) analysis was carried out using Kaplan-Meier 
estimates to draw out the cumulative HBeAg seroconversion rate curves. 
Univariate and multivariate analyses were performed using logistic regression 
models of relevant prognostic variables to construct the prediction model 
based on the risk index formula, and the equality of survival distribution was 
analyzed using Log-Rank test. All of the statistical tests were two-tailed and a 
p-value of < 0.05 was considered statistically significant. All procedures were 
performed using the SPSS for Windows version 12.0 (SPSS Inc., Chicago, IL, 
USA). 
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III. RESULTS 
 
1. Patient Characteristics 
Patient demographics and standard laboratory tests at the time of 
commencing lamivudine monotherapy are summarized in Table 1. The 
median age of the 748 patients (570 males, 178 females) was 43.0 years 
(range, 19 – 79). The mean pretreatment serum ALT level was 226.6 ± 8.4 
IU/L. The mean pretreatment HBV DNA level was 7.97 ± 0.4 log10 copies/mL. 
The mean duration of LAM treatment was 34.2 ± 0.7 months, and the mean 
follow up duration was 47.4 ± 0.8 months. 
 
 
Table 1. Baseline characteristics of HBeAg-positive CHB patients (n = 
748) 
Variables 
 
Gender 
 
Male, n (%) 570 (76.2) 
Female, n (%) 178 (23.8) 
Median age, years (range) 43.0 (19 – 79) 
Pretreatment serum ALT (IU/mL) 226.6 ± 8.4 
Pretreatment HBV DNA (log10 copies/mL) 7.97 ± 0.4 
Lamivudine treatment duration (months) 34.2 ± 0.7 
Follow up duration (months) 47.4 ± 0.8 
Results are given as mean ± standard error of mean, unless otherwise indicated. 
CHB, chronic hepatitis B; ALT, alanine aminotransferase; HBV, hepatitis B 
virus. 
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2. Cumulative HBeAg Seroconversion Rates 
Among the 748 patients, 316 (42.2%) achieved HBeAg seroconversion. 
Figure 1 represents the cumulative HBeAg seroconversion rates of the 748 
HBeAg-positive chronic hepatitis B patients. The cumulative HBeAg 
seroconversion rates were from 26.1% at 12 months to 50.7% at 96 months. 
 
 
Figure 1. Cumulative HBeAg seroconversion rate 
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3. Predictors of HBeAg Seroconversion 
Table 2 shows the comparisons of variables according to HBeAg 
seroconversion in HBeAg-positive chronic hepatitis B patients. In the 
univariate and multivariate analyses of the study set population, age (OR = 
0.974, 95% CI: 0.961-0.988, p < 0.001), pretreatment serum ALT level (OR = 
1.001, 95% CI: 1.000-1.002, p = 0.014), and pretreatment serum HBV DNA 
level (OR = 0.749, 95% CI: 0.651-0.862, p < 0.001) were independent factors 
for HBeAg seroconversion (Table 3). 
 
 
Table 2. Comparisons of variables according to HBeAg seroconversion in 
HBeAg-positive CHB patients 
Variables 
HBeAg seroconversion 
Not achieved Achieved 
(n = 432) (n = 316) 
Gender 
 
Male, n (%) 335 (77.5) 235 (74.4) 
Female, n (%) 97 (22.5) 81 (25.6) 
Age (years) 43.9 ± 0.5 40.7 ± 0.6 
Pretreatment serum ALT (IU/mL) 205.9 ± 8.7 254.9 ± 15.9 
Pretreatment HBV DNA (log10 copies/mL) 8.1 ± 0.1 7.8 ± 0.1 
Results are given as mean ± standard error of mean, unless otherwise indicated. 
CHB, chronic hepatitis B; ALT, alanine aminotransferase; HBV, hepatitis B virus. 
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Table 3. Univariate and multivariate analysis of variables according to HBeAg seroconversion in HBeAg-positive CHB patients 
Variables 
Univariate analysis  Multivariate analysis 
OR 95% CI P-value  OR 95% CI P-value 
Gender (Male:Female) 0.840 0.599 – 1.179 0.313  - - - 
Age (years) 0.974 0.960 – 0.987 < 0.001  0.974 0.961 – 0.988 < 0.001 
Pretreatment serum ALT (IU/mL) 1.001 1.000 – 1.002 0.006  1.001 1.000 – 1.002 0.014 
Pretreatment HBV DNA (log10 copies/mL) 0.772 0.673 – 0.885 < 0.001  0.749 0.651 – 0.862 < 0.001 
CHB, chronic hepatitis B; ALT, alanine aminotransferase; HBV, hepatitis B virus; OR, odds ratio; CI, confidence intervals. 
 
 
Table 4. Logistic regression analysis of maximum likelihood estimates for HBeAg seroconversion in HBeAg-positive CHB patients  
Variables β S.E. P-value Exp(β) 
Constant 2.8844 0.6676 <0.0001 17.893 
Age (years) -0.0262 0.0071 0.0002 0.974 
Pretreatment serum ALT (IU/mL) 0.000915 0.0004 0.0138 1.001 
Pretreatment HBV DNA (log10 copies/mL) -0.2889 0.0715 0.0001 0.749 
CHB, chronic hepatitis B; ALT, alanine aminotransferase; HBV, hepatitis B virus; S.E., standard error; Exp, exponential. 
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4. Model building: Individual Prediction Model for HBeAg 
Seroconversion 
Based on the three variables – age, pretreatment serum ALT level, and 
pretreatment HBV DNA level – an individual prediction model (risk index 
formula) for HBeAg seroconversion was constructed (Table 4). The 
regression formula (risk index) for prediction of HBeAg seroconversion is:  
 
Risk index (RI) for HBeAg seroconversion = e
A
 
The probability of HBeAg seroconversion = RI/(RI+1) 
where A = 2.8844 + [-0.0262 x Age (year)] + [0.000915 x pretreatment 
serum ALT level (IU/L)] + [-0.2889 x pretreatment HBV DNA level 
(log10 copies/ml)] 
 
 
Figure 2. Classification of lamivudine response group in accordance with the 
probability of HBeAg seroconversion 
 
 
 
* Pr: Probability of HBeAg seroconversion 
Predicted Probability for 
HBeAg Seroconversion 
0.3 < Pr
*
 < 0.5 
Intermediate responders 
Pr
*
 ≤ 0.3 
Low responders 
Pr
*
 ≥ 0.5 
High responders 
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All possible probabilities for HBeAg seroconversion of 748 patients were 
calculated and realigned, and two arbitrary cut-off values were selected to 
exclude spontaneous HBeAg seroconversion rate from the accumulated 
HBeAg seroconversion rate during the lamivudine treatment period. Based on 
the cut-off values, the probability of HBeAg seroconversion was categorized 
into high (Pr ≥ 50%), intermediate (30% < Pr < 50%), and low (Pr ≤ 30%) 
response groups as depicted in Figure 2. In the high response group, 55.5% of 
the patients achieved HBeAg seroconversion whereas in the low response 
group, 19.4% achieved HBeAg seroconversion (Table 5).  
 
 
Table 5. Distribution of HBeAg CHB patients with HBeAg seroconversion in 
accordance with the individual prediction model in the estimation set (p < 0.001) 
 
HBeAg Seroconversion 
Total 
Not achieved Achieved 
Response group, 
n (%) 
Low 75 (80.6) 18 (19.4) 93 (12.4) 
Intermediate 280 (57.9) 204 (42.1) 484 (64.7) 
High 77 (45.0) 94 (55.5) 171 (22.9) 
Total 432 (57.8) 316 (42.2) 748 (100.0) 
 
 
The cumulative rate of HBeAg seroconversion according to the individual 
prediction model reveals that there is a significant difference in the 
cumulative HBeAg seroconversion rates between the response groups, as 
shown in Figure 3 (p < 0.001). For the high response group, the cumulative 
HBeAg seroconversion rates at 12, 24, 36, and 60 months were 36.3%, 44.1%, 
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54.9%, and 63.1%, respectively. For the intermediate response group, the 
cumulative HBeAg seroconversion rates at 12, 24, 36, and 60 months were 
25.4%, 34.4%, 39.7%, and 46.8%, respectively. The cumulative HBeAg 
seroconversion rate for the low response group was 10.8% at 12 months, 
16.6% at 24 months, 18.2% at 36 months, 21.8% at 60 months, and remained 
unchanged throughout the follow up period. 
 
 
Figure 3. Cumulative rate of HBeAg seroconversion in accordance with the 
individual prediction model in the estimation set (p < 0.001) 
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5. Validation of Individual Prediction Model 
Table 6 shows baseline patient demographics and laboratory tests of the 
validation set population. The median age of the 396 patients (280 males, 116 
females) was 41.0 years (range, 18 – 77). The mean pretreatment serum ALT 
level was 170.0 ± 10.6 IU/L. The mean pretreatment HBV DNA level was 7.4 
± 0.1 log10 copies/mL. The mean follow up duration was 22.3 ± 0.5 months. 
Compared with the study set population, patients in the validation set were 
younger in age (p = 0.011), had lower serum ALT levels (p < 0.001) and 
pretreatment HBV DNA levels (p < 0.001), and shorter follow up duration 
period (p < 0.001).  
 
 
 
Table 6. Baseline characteristics of HBeAg-positive CHB patients in the 
validation set (n = 396) 
Variables 
 
Gender 
 
Male, n (%) 280 (70.7) 
Female, n (%) 116 (29.3) 
Median age, years (range) 41.0 (18 – 77) 
Pretreatment serum ALT (IU/mL) 170.0 ± 10.6 
Pretreatment HBV DNA (log10 copies/mL) 7.4 ± 0.1 
Follow up duration (months) 22.3 ± 0.5 
Results are given as mean ± standard error of mean, unless otherwise indicated. 
CHB, chronic hepatitis B; ALT, alanine aminotransferase; HBV, hepatitis B virus. 
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Figure 4. Cumulative HBeAg seroconversion rate of the validation set 
 
 
 
The cumulative HBeAg seroconversion rates were from 13.1% at 12 months 
to 34.2% at 36 months (Figure 4). For the high response group, the cumulative 
HBeAg seroconversion rates at 12, 24, and 36 months were 16.2%, 30.1%, 
and 45.5%, respectively. For the intermediate response group, the cumulative 
HBeAg seroconversion rates at 12, 24, and 36 months were 11.1%, 22.5%, 
and 27.5%, respectively. The cumulative HBeAg seroconversion rate for the 
low response group was 13.3% at 12 months, and remained unchanged 
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throughout the follow up period (Figure 5). 
Based on the predefined categorization, 30.7% of the high response group 
gained HBeAg seroconversion, and 11.5% of the low response group 
achieved HBeAg seroconversion (Table 7).  
According to the individual prediction model, there was a significant 
difference in the cumulative rate of HBeAg seroconversion between high 
response group and intermediate and low response group as shown in Figure 5 
(p = 0.0149). 
 
Figure 5. Cumulative rate of HBeAg seroconversion in accordance with the 
individual prediction model in the validation set (p = 0.0149) 
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Table 7. Distribution of HBeAg CHB patients with HBeAg seroconversion in 
accordance with the individual prediction model in the validation set (p < 0.013) 
 
HBeAg Seroconversion 
Total 
Not achieved Achieved 
Response group, 
n (%) 
Low 23 (88.5) 3 (11.5) 26 (6.6) 
Intermediate 186 (80.9) 44 (19.1) 230 (58.1) 
High 97 (69.3) 43 (30.7) 140 (35.4) 
Total 306 (77.3) 90 (22.7) 396 (100.0) 
CHB, chronic hepatitis B. 
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IV. DISCUSSION 
 
Sustained suppression of viral replication and achieving loss of HBeAg 
and/or seroconversion to anti-HBe in HBeAg-positive patients are the most 
important goals in the treatment of chronic HBV infection.
35
 Among these 
goals, HBeAg seroconversion is a desirable goal, because achievement of 
complete HBeAg seroconversion usually predicts long-lasting suppression of 
HBV, reduced infectivity and an improved clinical prognosis.
8, 36
 
In the current study, an individual prediction model for HBeAg 
seroconversion in HBeAg-positive chronic hepatitis B patients on lamivudine 
monotherapy was developed from routinely measured and easily available 
clinical and laboratory variables.  
Predictors associated with HBeAg seroconversion in HBeAg-positive 
chronic hepatitis B patients on lamivudine monotherapy were patient’s age, 
pretreatment serum ALT level, and pretreatment serum HBV DNA level. 
Pretreatment serum HBV DNA level was negatively associated with the 
probability of HBeAg seroconversion, as previously reported.
35, 37-39
 Although 
there has been conflicting data on the affect of age and pretreatment serum 
ALT level on the treatment outcome of antiviral therapy using nucleos(t)ide 
analogues in HBeAg-positive chronic hepatitis B patients, younger age and 
higher serum ALT level at the initiation of antiviral therapy were associated 
with higher probability of HBeAg seroconversion in the current study.
35, 37, 39, 
40
 It could be postulated that patients with higher serum ALT levels undergo 
more intense immune responses, and thus, have a higher change of HBeAg 
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seroconversion.  
The role of genotypes as a treatment predictor in chronic hepatitis B has not 
been clearly defined and remains controversial.
41-45
 Although there is an 
increasing evidence that HBV genotype may be an important predictor of 
treatment outcome of interferon-based therapy, the role of HBV genotypes in 
nucleos(t)ide analogue antiviral therapy remains controversial. In Korea, more 
than 95% of chronic hepatitis B patients are infected with genotype C, and 
thus, individual HBV genotyping was not performed in the current study, with 
an assumption that the only a minority of patients have HBV genotypes other 
than genotype C.
46-48
 
The cut-off values for the response group categorization in the individual 
prediction model were selected under the background of natural history of 
chronic hepatitis B infection and reported long-term treatment results of 
lamivudine therapy. According to the literature, the annual rate of spontaneous 
HBeAg seroconversion is approximately 15-20%, and therefore the lower 
cut-off value of 30% was chosen roughly to exclude spontaneous HBeAg 
seroconversion rate from the accumulated HBeAg seroconversion rate during 
the lamivudine treatment period.
49-51
 The incidence of HBeAg seroconversion 
at 5 years of lamivudine treatment is approximately 50%, and hence it was 
chosen for the upper cut-off value for the individual prediction model.
5
 
The HBeAg seroconversion rate in the validation set was lower than that in 
the study set. In this cohort of 748 patients of the study set, 50.7% achieved 
HBeAg seroconversion with up to 96 months, which is comparable with the 
results of previous studies.
5, 52
 On the other hand, 45.4% achieved HBeAg 
seroconversion with up to 48 months. Similar to the literature, the chance of 
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HBeAg seroconversion increased with time, thus it could be postulated that 
the study set showed a higher HBeAg seroconversion rate compared to that of 
the validation set, owing to a longer duration of lamivudine treatment.
15, 25, 53, 
54
 Therefore if the follow up duration of the validation set was extended to a 
longer period of time, HBeAg seroconversion rate might rise to a comparable 
level. 
In both of the study and the validation sets, the cumulative HBeAg 
seroconversion rate increased with time significantly in the high response 
group. The cumulative HBeAg seroconversion rate increased from 36.3% at 1 
year to 63.2% at 5 years in the high response group of the study set, and 
16.2% at 1 year to 61.3% at 4 years in the high response group of the 
validation set, respectively. 
On the contrary, the cumulative HBeAg seroconversion rate of the low 
response groups of both sets remained at a low level from the early period of 
time. In the study set, the cumulative HBeAg seroconversion rate was 10.8% 
at 1 year and increased to 21.8% at 4 years, but no longer increased up to 7 
years. In the validation set, the cumulative HBeAg seroconversion rate was 
13.3% at 1 year and remained the same throughout the follow up period. 
Accordingly, complete HBeAg seroconversion is hardly achieved in the low 
response group, thus there is a higher probability of developing virologic 
breakthrough during the lamivudine therapy. Once virologic breakthrough has 
taken place, adding adefovir dipivoxil to lamivudine treatment may be an 
answer to the treatment plan, yet it would be less cost-effective than choosing 
a newer and potent antiviral drug, such as entecavir, in the beginning of 
antiviral treatment for the patients in the low response group. 
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Likewise, for the treatment-naïve patients of younger age with high serum 
ALT levels and low HBV DNA levels, favorable response to lamivudine is 
anticipated. In such patients, treating with lamivudine would be cost-effective 
than with high barrier drugs as entecavir. 
The patients in the intermediate response group showed a moderate increase 
in cumulative HBeAg seroconversion rate in both of the study and the 
validation set. In this case, antiviral therapy may be started with lamivudine 
and perform on-treatment monitoring of the serum HBV DNA at 12 weeks to 
determine primary treatment failure. Patients with complete suppression of 
serum HBV DNA level at 12 weeks of therapy may be continued with 
lamivudine as early virologic response monitoring at 12 weeks predicts 
HBeAg seroconversion (data not shown). Further studies are need for 
determining new, tailored antiviral treatment strategies for the patients in the 
intermediate group. 
The major limitation of this study was that the validation study was carried 
out in a single institution with a shorter follow up duration compared to that of 
the study set population. For this reason, the significant differences between 
the response groups were not clear. Due to these limitations, further studies 
with a long-term accumulated data would be necessary. 
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V. CONCLUSION 
 
In conclusion, an individual prediction model for HBeAg seroconversion in 
HBeAg-positive chronic hepatitis B patients on lamivudine monotherapy was 
developed from routinely measured and easily available clinical and 
laboratory variables. For the patients in the high response group, commencing 
antiviral therapy with lamivudine for the long-term management would be 
appropriate, for they are likely to have favorable outcomes with lamivudine. 
Further studies are needed for the patients in the intermediate response group. 
Lamivudine monotherapy is not recommended for the patients in the low 
response group. This individual prediction model is expected to contribute to 
establishing new, tailored antiviral treatment guidelines for chronic hepatitis B 
patients. 
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ABSTRACT (IN KOREAN) 
 
HBeAg 양성 만성 B형 간염 환자에서 
라미부딘의 치료 효과 및 예측모형의 개발 
 
<지도교수  한 광 협> 
 
연세대학교 대학원 의학과 
 
강 원 석 
 
배경: B형 간염바이러스의 증식을 억제하는 라미부딘은 만성 B형 
간염에서의 장기적인 효용성 및 안정성이 밝혀져 있으나 최근 약제 
내성 바이러스가 출현함에 따라 문제가 되고 있으나 경제적인 
측면과 장기간 연구된 약제 안정성으로 인하여 라미부딘은 
아직까지도 만성 B형 간염 치료에 있어서 널리 쓰이고 있다. 따라서 
라미부딘 내성 바이러스의 발생 가능성이 적고 라미부딘 치료에 
효과적인 반응을 보이는 환자들을 선별하는 것이 중요하다.  
방법: 1999년 1월부터 2006년 8월까지 라미부딘 1일 100mg씩 6개월 
이상 단독 치료를 받은 만성 B형 간염 환자 중 HBeAg 양성인 환자 
748명을 대상으로 분석하였다. 단변량 및 다변량 분석을 통하여 
HBeAg 혈청전환의 예측인자를 구한 뒤 로지스틱 회귀 분석을 
이용하여 HBeAg 혈청전환의 확률을 산출하고 예측모형을 
개발하였다. 예측 모형에 따라 고반응군(Pr≥50%), 중간반응군 
(30<Pr<50%), 저반응군(Pr≤30%)으로 분류한 뒤 2005년 1월부터 
2006년 12월까지 라미부딘을 새로 투약 받은 환자 396명을 
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대상으로 예측모형을 검증하였다.  
결과: 라미부딘 단독치료의 중앙 기간은 34.2개월이었다. HBeAg의 
누적 혈청전환율은 12개월째 26.1%에서 96개월째 50.7%로 
증가하였다. HBeAg 혈청전환의 예측인자로는 환자의 나이(OR=0.974, 
95% CI: 0.961-0.988, p<0.001), 치료전 ALT 수치(OR=1.001, 95% CI: 
1.000-1.002, p=0.014), 그리고 치료 전 HBV DNA 수치(OR=0.749, 95% 
CI: 0.651-0.862, p<0.001)였다. 예측모형을 바탕으로 한 고반응군, 
중간반응군, 저반응군에서의 HBeAg의 72개월 누적 혈청전환율은 
각각 66.0%, 48.5%, 21.8% 이었다 (p<0.001). 
결론: HBeAg 양성 만성 B형 간염 환자에서 라미부딘 단독 치료시 
HBeAg 혈청전환 예측모형을 개발하였다. 이 예측 모형을 통하여 
항바이러스 치료를 시작하기 전 라미부딘 치료의 반응을 
예측함으로써 새로운 항바이러스 치료 가이드라인을 형성하는 데 
도움이 될 것으로 생각된다. 
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핵심되는 말 : 예측모형, 만성 간염, 라미부딘, 치료 
